<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PLICAMYCIN</span><br/>(plik-a-mi'cin)<br/><span class="topboxtradename">Mithracin, </span><span class="topboxtradename">Mithramycin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antibiotic</span><br/><b>Prototype: </b>Doxorubicin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2500 mcg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Cytotoxic antibiotic produced by <i>Streptomyces plicatus,</i> with minimal immunosuppressive activity. Complexes with DNA, thus inhibiting DNA-directed RNA synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>May lower serum calcium levels by unclear mechanism. Appears to block hypercalcemic action of vitamin D, and may inhibit parathyroid
         hormone effect on osteoclasts. Interferes with synthesis of various clotting factors. High toxicity with low therapeutic index
         limits clinical use.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To treat hospitalized patients with hypercalcemia or hypercalciuria associated with advanced neoplasms and to treat testicular
         malignancy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Bleeding and coagulation disorders, myelosuppression; electrolyte imbalance (especially hypocalcemia, hypokalemia, hypophosphatemia);
         pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with prior abdominal or mediastinal radiology; liver or renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Neoplasia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 2530 mcg/kg once/d for 810 d or until toxicity necessitates discontinuing (max: 30 mcg/kg/d for 10 d)<br/><br/><span class="indicationtitle">Malignant Hypercalcemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 25 mcg/kg once/d for 34 d, may repeat after 1 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Base drug dose on ideal body weight when edema, ascites, or hydrothorax is present.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute each 2.5 mg with 4.9 mL of sterile water to yield 500 mcg/mL. Withdraw the calculated dose and further dilute in 1000
                  mL of D5W or D5/NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give at a rate of 46 h per liter. Regulate IV flow rate carefully (established by physician); GI adverse effects increase
                  when rate is too fast. Terminate infusion immediately if extravasation occurs. Apply moderate heat to disperse the drug and
                  to minimize tissue irritation.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b> Cefepime.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Discard unused portions of reconstituted solution and prepare new ones daily.</li>
<li>Refrigerate unreconstituted vials at 2°8° C (36°46° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, irritability, dizziness, weakness, headache, mental depression. <span class="typehead">GI:</span>
<span class="speceff-common">Stomatitis, anorexia, nausea, vomiting, diarrhea,</span> widespread intestinal hemorrhage. <span class="typehead">Hematologic:</span> Thrombocytopenia, <span class="speceff-life">bleeding and coagulation disorders</span> (dose related), leukopenia (mild). <span class="typehead">Body as a Whole:</span> Fever, marked facial flushing, hemoptysis, abnormal liver and renal function tests. <span class="typehead">Skin:</span> Nonspecific or acneiform skin rash, phlebitis. <span class="typehead">Metabolic:</span> Hypophosphatemia, hypokalemia, hypocalciuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concomitant administration of <b>vitamin D</b> may enhance hypercalcemia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Crosses bloodbrain barrier; appears to localize in areas of bone active resorption. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>
            							Note: Therapy is usually interrupted if leukocyte count is 3, if platelet count is 3, or if PT is &gt;4 sec higher than control (normal: 1214 sec).
            						
         </li>
<li>Establish flow chart at beginning of therapy, permitting continuous record of weight and I&amp;O ratio and pattern.</li>
<li>Lab tests: Perform frequent assessments of liver and hematologic (platelet count, bleeding and prothrombin times) and kidney
            function throughout therapy and for several days after last dose; periodic serum electrolytes.
         </li>
<li>Report marked facial flushing. It is often an early symptom or thrombocytopenia, which frequently is evidenced by a single
            or persistent episode of epistaxis or hematemesis; may be rapid in onset during or after a course of treatment.
         </li>
<li>Inspect skin daily for signs of purpura. Report hemoptysis immediately, which may occur because of bleeding into metastasis.</li>
<li>
            							Note: Rebound hypercalcemia (normal: 910.6 mg/dL) following plicamycin-induced hypocalcemia may persist 24 d (see Appendix
            F).
            						
         </li>
<li>Monitor I&amp;O ratio to assure adequate fluid intake; the hypercalcemia patient may be dehydrated.</li>
<li>Monitor for S&amp;S of adverse effects on the GI mucosal cells (hematemesis, melena) that will necessitate stopping drug use.</li>
<li>Check patient's bowel function daily to prevent high fecal impaction due to diminished peristalsis.</li>
<li>Consult physician about dietary calcium intake and coordinate dietary planning with dietitian, patient, and family.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use a reliable form of birth control during and for several months following completion of treatment with plicamycin.</li>
<li>Report easy bruising or bleeding immediately to your physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>